readthroughSign in
Jul 14, 2026Partnership

Capricor discloses San Diego HQ lease tied to Deramiocel FDA decision

The company signed a lease for a new headquarters with rent terms and a termination clause linked to FDA approval by December 31, 2026.

Capricor Therapeutics disclosed in a Form 8-K that on July 9, 2026, it entered into a Lease Agreement with ARE-SD Region No. 39 Owner, LLC for approximately 171,000 rentable square feet located at 9625 Towne Centre Drive, San Diego, California, to be used as Capricor's new headquarters, including expanded manufacturing cleanrooms, research and development laboratory, administrative offices and other related uses.1

The lease start date is tied to regulatory timing. The term of the Lease is estimated to commence on the date that is the earlier of (i) the date on which Capricor's lease contingency related to FDA approval is satisfied or waived or (ii) December 31, 2026.1 The rent commencement date will be twelve months after such commencement date, and the term of the Lease will end 138 months from the first day of the first full month following the rent commencement date.1

On financial terms, the initial monthly base rent is $5.60 per rentable square foot, or approximately $958,000 per month, subject to annual increases of 3.0%.1 Capricor will receive an 18-month full base rent abatement beginning on the Rent Commencement Date, followed by an additional six-month partial base rent abatement during which base rent will be payable on only 128,068 rentable square feet of the approximately 171,000 rentable square foot premises, and thereafter base rent will be payable on the entire premises.1 The Landlord will provide Capricor with a tenant improvement allowance, Capricor will provide a security deposit of approximately $958,000 in cash or in the form of a letter of credit, and Capricor will also be responsible for real property taxes, building insurance, routine maintenance and operating costs under the terms of the Lease.1

The lease includes a specific exit provision: if Capricor does not receive FDA approval of Deramiocel for the treatment of Duchenne muscular dystrophy by December 31, 2026, then either Capricor or Landlord may terminate the Lease by delivering written notice within five business days after such date.1

The full lease text is expected to be filed as an exhibit to Capricor's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.